Definitive Healthcare (NASDAQ:DH) Given New $3.00 Price Target at The Goldman Sachs Group

Definitive Healthcare (NASDAQ:DH) had its target price decreased by The Goldman Sachs Group from $4.50 to $3.00 in a research note published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Several other brokerages have also recently commented on DH. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Barclays lowered their price target on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research note on Monday. Finally, Stephens began coverage on Definitive Healthcare in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Definitive Healthcare has a consensus rating of “Hold” and a consensus target price of $5.35.

Definitive Healthcare Price Performance

Shares of NASDAQ DH opened at $2.78 on Tuesday. The firm has a market capitalization of $321.15 million, a PE ratio of -0.90, a P/E/G ratio of 4.06 and a beta of 1.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. Definitive Healthcare has a 1-year low of $2.58 and a 1-year high of $8.82. The business’s fifty day moving average price is $4.58 and its two-hundred day moving average price is $4.47.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The firm had revenue of $62.29 million for the quarter, compared to analyst estimates of $60.60 million. On average, research analysts expect that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Trading of Definitive Healthcare

A number of large investors have recently bought and sold shares of the stock. Western Wealth Management LLC bought a new stake in Definitive Healthcare in the fourth quarter valued at $90,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Definitive Healthcare by 6.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company’s stock worth $334,000 after purchasing an additional 4,748 shares during the last quarter. Sone Capital Management LLC bought a new stake in shares of Definitive Healthcare during the fourth quarter worth $953,000. Two Sigma Advisers LP grew its holdings in shares of Definitive Healthcare by 1,301.5% during the fourth quarter. Two Sigma Advisers LP now owns 189,200 shares of the company’s stock worth $778,000 after purchasing an additional 175,700 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Definitive Healthcare by 2,383.1% during the fourth quarter. Two Sigma Investments LP now owns 285,555 shares of the company’s stock worth $1,174,000 after purchasing an additional 274,055 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.